Staff Contact: Jane Drummond
The Missouri Senate on April 25 perfected a Senate substitute for SB 751, which prohibits pharmaceutical manufacturers from restricting the number of contract pharmacies that may be used by entities participating in the 340B Drug Pricing Program. The bill must receive a final vote in the Senate before moving to the House for consideration. The House previously approved substantially similar language in HB 2267. If the House adopts the Senate language without any changes, the measure will head to the governor’s desk for signature.